专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明申请

WO2004033431A2 HYDROXYPYRAZOLES AND METHODS OF PROPHYLAXIS OR TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF 审中-公开
标题翻译：羟基吡唑和预防或治疗代谢相关疾病的方法
公开(公告)号：WO2004033431A2
公开(公告)日：2004-04-22
申请号：PCT/US2003/031509
申请日：2003-10-02
申请人： ARENA PHARMACEUTICALS, INC. , SEMPLE, Graeme , SHIN, Young, Jun
发明人： SEMPLE, Graeme , SHIN, Young, Jun
IPC分类号： C07D231/00
CPC分类号： C07D401/06 , C07D401/14 , C07D403/06
摘要： The present invention relates to certain hydroxypyrazole derivatives of Formula (I), and pharmaceutically acceptable salts thereof, which exhibit useful pharmaceutical properties, for example as agonists for the nicotinic acid receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the prophylaxis or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for the use of the compounds of the invention in combination with other active agents such as those belonging to the class of α-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers and the like.
摘要翻译：本发明涉及某些表现出有用的药物性质的式（I）的羟基吡唑衍生物及其药学上可接受的盐，例如作为烟酸受体的激动剂。本发明还提供含有本发明化合物的药物组合物，以及使用本发明化合物和组合物预防或治疗代谢相关疾病（包括血脂异常，动脉粥样硬化，冠心病，胰岛素抵抗，类型 2型糖尿病，综合征X等。此外，本发明还提供本发明化合物与其它活性剂如属于α-葡糖苷酶抑制剂类，醛糖还原酶抑制剂，双胍类，HMG-CoA还原酶抑制剂，角鲨烯合成抑制剂，贝特类，LDL分解代谢增强剂，血管紧张素转换酶（ACE）抑制剂，胰岛素分泌增强剂等。

22. 发明申请

WO2002090333A1 NOVEL PYRIDINONE AND RELATED HETEROCYCLIC DERIVATIVES 审中-公开
标题翻译：新颖的吡啶酮和相关的杂环衍生物
公开(公告)号：WO2002090333A1
公开(公告)日：2002-11-14
申请号：PCT/SE2002/000839
申请日：2002-04-29
申请人： ASTRAZENECA AB , JOHANSSON, Magnus , ROSENQUIST, Åsa , SEMPLE, Graeme
发明人： JOHANSSON, Magnus , ROSENQUIST, Åsa , SEMPLE, Graeme
IPC分类号： C07D213/64
CPC分类号： C07D213/64 , A61K31/4412 , A61K31/4439 , A61K31/496 , A61K31/506 , A61K31/513 , C07D213/74 , C07D237/14 , C07D239/22
摘要： The present invention relates to a compound of formula (1), (2) or (3) having the following structures: Formula 1, 2, 3 wherein X, Y, and Z are independently C or N; A is a direct bond, CH2 or NH;B is a direct bond or NH; n= 0-2; R1 is H, optionally substituted C 1-4 191 alkyl, C 3-7 191 cycloalkyl, halogen, cyano, nitro, aryl, or alkylaryl; R2 is H, C 1-4 191 alkyl, or alkoxy C 1-4 191 alkyl;or R1 and R2 are taken together to form an unsaturated 6-membered aromatic or heterocyclic ring containing one or two heteroatoms fused to the pyridone; R3 is a direct bond, H, C 1-4 191 alkyl, substituted C 1-4 191 alkyl, C 3-7 191 cycloalkyl, aryl or alkylaryl; R4 is a direct bond or H; R5 is C 1-4 191 alkyl or aryl; R6 and R7 are independently H or C 1-4 191 alkyl; R8 and R9 are independently H, C 1-4 191 alkyl, or tert -butoxycarbonyl or R8 and R9 are taken together with the nitrogen to which they are attached and form optionally, unsubstituted, substituted, fused or unsaturated 5-,6-,7-membered heterocycles containing one or two heteroatoms wherein said substituents are selected from the group consisting of hydroxyl, hydroxymethyl, carboxymethyl, carboxy, methoxy, and tert -butoxy;as ( R )-enantiomers, ( S )-enantiomers or a racemate in the form of a free base or a pharmaceutically acceptable salt or solvate thereof.
摘要翻译：本发明涉及具有以下结构的式（1），（2）或（3）的化合物：式1，2，3其中X，Y和Z独立地为C或N; A是直接键，CH2或NH; B是直接键或NH; n = 0-2; R 1为H，任选取代的C 1-419烷基，C 3-7191环烷基，卤素，氰基，硝基，芳基或烷基芳基; R2是H，C1-4191烷基或烷氧基C1-4191烷基;或R1和R2一起形成含有一个或两个与吡啶酮稠合的杂原子的不饱和6元芳族或杂环; R3是直接键，H，C1-4191烷基，取代的C1-4191烷基，C3-7191环烷基，芳基或烷基芳基; R4是直接键或H; R5是C1-4191烷基或芳基; R6和R7独立地是H或C1-4191烷基; R 8和R 9独立地是H，C 1-419烷基或叔丁氧基羰基，或者R 8和R 9与它们所连接的氮一起形成，任选地是未取代的，取代的，稠合的或不饱和的5-，6-，含有一个或两个杂原子的多元杂环，其中所述取代基选自羟基，羟甲基，羧甲基，羧基，甲氧基和叔丁氧基;作为（R） - 对映异构体，（S） - 对映异构体或形式的外消旋物的游离碱或其药学上可接受的盐或溶剂化物。

23. 发明申请

WO1993016999A1 BENZODIAZEPIN DERIVATIVES USEFUL AS CCK-RECEPTOR ANTAGONISTS 审中-公开
标题翻译：作为CCK受体拮抗剂，苯并二氮吡啶衍生物有用
公开(公告)号：WO1993016999A1
公开(公告)日：1993-09-02
申请号：PCT/GB1993000404
申请日：1993-02-26
申请人： YAMANOUCHI PHARMACEUTICAL CO. LTD. , FERRING RESEARCH LIMITED , RYDER, Hamish , SEMPLE, Graeme , KENDRICK, David, Alan , SZELKE, Michael , SATOH, Masato , OHTA, Mitsuaki , MIYATA, Keiji , NISHIDA, Akito
发明人： YAMANOUCHI PHARMACEUTICAL CO. LTD. , FERRING RESEARCH LIMITED
IPC分类号： C07D243/24
CPC分类号： C07D401/04 , C07D243/24 , C07D403/06
摘要： A benzodiazepine derivative of formula (I), or a pharmaceutically acceptable salt thereof, wherein (a) R is -CH2CHOH(CH2)aR or a ketone group -CH2CO(CH2)aR in which a is 0 or 1 and R and R are selected from alkyl and cycloalkyl groups and saturated heterocyclic groups optionally substituted at a hetero-atom; (b) R and R are independently selected from aromatic carbocyclic and heterocylic residues; and (c) W and X are selected independently from halogen and hydrogen atoms and alkyl and alkoxy groups. These compounds are gastrin and/or CCK-B receptor antagonists.
摘要翻译：式（I）的苯并二氮杂衍生物或其药学上可接受的盐，其中（a）R 1是-CH 2 CHOH（CH 2）aR 4或酮基-CH 2 CO（CH 2）a R 5，其中a 是0或1，R 4和R 5选自烷基和环烷基和任选在杂原子处被取代的饱和杂环基; （b）R 2和R 3独立地选自芳族碳环和杂环残基; 和（c）W和X独立地选自卤素和氢原子以及烷基和烷氧基。这些化合物是胃泌素和/或CCK-B受体拮抗剂。

24. 发明申请

WO2009105206A1 MODULATORS OF THE HISTAMINE H3 RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO 审中-公开
标题翻译：用于治疗相关疾病的组胺H3受体的调节剂
公开(公告)号：WO2009105206A1
公开(公告)日：2009-08-27
申请号：PCT/US2009/001022
申请日：2009-02-18
申请人： ARENA PHARMACEUTICALS, INC. , SANTORA, Vincent J. , HOFILENA, Brian J. , PULLEY, Michelle , SEMPLE, Graeme , SHAN, Yun , SMITH, Brian M.
发明人： SANTORA, Vincent J. , HOFILENA, Brian J. , PULLEY, Michelle , SEMPLE, Graeme , SHAN, Yun , SMITH, Brian M.
IPC分类号： C07D217/14 , C07D401/10 , C07D401/14 , C07D403/10 , C07D403/14 , C07D405/14 , A61K31/472 , A61P25/00
CPC分类号： C07D401/10 , C07D217/14 , C07D401/14 , C07D403/10 , C07D403/14 , C07D405/14
摘要： Amide derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the histamine H3 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of histamine H3-associated disorders, such as cognitive disorders, epilepsy, brain trauma, depression, obesity, disorders of sleep and wakefulness such as excessive daytime sleepiness, narcolepsy, shift-work sleep disorder, drowsiness as a side effect from a medication, maintenance of vigilance to aid in the completion of tasks and the like, cataplexy, hypersomnia, somnolence syndrome, jet lag, sleep apnea and the like, attention deficit hyperactivity disorder (ADHD), schizophrenia, allergies, allergic responses in the upper airway, allergic rhinitis, nasal congestion, dementia, Alzheimer's disease, pain and the like.
摘要翻译：式（Ia）的酰胺衍生物及其药物组合物，其调节组胺H3受体的活性。本发明化合物及其药物组合物涉及可用于治疗组胺H3相关疾病如认知障碍，癫痫，脑外伤，抑郁症，肥胖症，睡眠障碍和觉醒症如白天过度嗜睡，发作性睡病的方法，换班工作睡眠障碍，作为药物副作用的嗜睡，维持警惕以帮助完成任务等，猝倒，睡眠过多，嗜睡综合征，时差，睡眠呼吸暂停等，注意力缺陷多动障碍（ADHD），精神分裂症，过敏，上呼吸道过敏反应，过敏性鼻炎，鼻塞，痴呆，阿尔茨海默病，疼痛等。

25. 发明申请

WO2008048609A1 BIPHENYL SULFONYL AND PHENYL-HETEROARYL SULFONYL MODULATORS OF THE HISTAMINE H3-RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO 审中-公开
标题翻译：用于治疗相关疾病的组胺H3受体的联苯磺隆和苯并噻吩磺酸盐调节剂
公开(公告)号：WO2008048609A1
公开(公告)日：2008-04-24
申请号：PCT/US2007/022086
申请日：2007-10-16
申请人： ARENA PHARMACEUTICALS, INC. , SANTORA, Vincent, J. , HART, Ryan, M. , IBARRA, Jason, B. , PARK, Douglas, M. , REN, Albert, S. , SEMPLE, Graeme , SCHULTZ, Jeffrey, A. , SMITH, Brian , SMITH, Jeffrey
发明人： SANTORA, Vincent, J. , HART, Ryan, M. , IBARRA, Jason, B. , PARK, Douglas, M. , REN, Albert, S. , SEMPLE, Graeme , SCHULTZ, Jeffrey, A. , SMITH, Brian , SMITH, Jeffrey
IPC分类号： C07D207/06 , C07D401/12 , C07D403/10 , C07D405/12 , C07D409/10 , C07D417/10 , A61K31/506 , A61P25/28
CPC分类号： C07D207/06 , C07D401/12 , C07D403/10 , C07D405/12 , C07D409/10 , C07D417/10
摘要： The present invention relates to certain biphenyl sulfonamide derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the histamine H3- receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of histamine H3-associated disorders, such as, cognitive disorders, epilepsy, brain trauma, depression, obesity, disorders of sleep and wakefulness such as narcolepsy, shift-work syndrome, drowsiness as a side effect from a medication, maintenance of vigilance to aid in completion of tasks and the like, cataplexy, hypersomnia, somnolence syndrome, jet lag, sleep apnea and the like, attention deficit hyperactivity disorder (ADHD), schizophrenia, allergies, allergic responses in the upper airway, allergic rhinitis, nasal congestion, dementia, Alzheimer's disease and the like.
摘要翻译：本发明涉及式（Ia）的某些联苯磺酰胺衍生物及其药物组合物，其调节组胺H3受体的活性。本发明的化合物及其药物组合物涉及可用于治疗组胺H3相关疾病例如认知障碍，癫痫，脑外伤，抑郁症，肥胖症，睡眠障碍和觉醒症如发作性睡眠，工作综合征，作为药物副作用的睡意，维持警惕以完成任务等，猝倒，睡眠过多，嗜睡症，时差，睡眠呼吸暂停等，注意力缺陷多动障碍（ADHD），精神分裂症过敏，上呼吸道过敏反应，过敏性鼻炎，鼻塞，痴呆，阿尔茨海默氏病等。

26. 发明申请

WO2005007658A2 FUSED-ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO 审中-公开
标题翻译：作为代谢物和丙肝的调节剂和与之相关的疾病的治疗的融合的ARYL和HETEROARYL衍生物
公开(公告)号：WO2005007658A2
公开(公告)日：2005-01-27
申请号：PCT/US2004/022417
申请日：2004-07-13
申请人： ARENA PHARMACEUTICALS, INC. , JONES, Robert, M. , SEMPLE, Graeme , XIONG, Yifeng , SHIN, Young-Jun , REN, Albert, S. , CALDERON, Imelda , FIORAVANTI, Beatriz , CHOI, Jin, Sun, Karoline , SAGE, Carlton, R.
发明人： JONES, Robert, M. , SEMPLE, Graeme , XIONG, Yifeng , SHIN, Young-Jun , REN, Albert, S. , CALDERON, Imelda , FIORAVANTI, Beatriz , CHOI, Jin, Sun, Karoline , SAGE, Carlton, R.
IPC分类号： C07D487/04
CPC分类号： C07D215/233 , C07D471/04 , C07D473/00 , C07D487/04
摘要： The present invention relates to certain fused aryl and heteroaryl derivatives of Formula (I) that are modulators of metabolism. Accordingly, compounds of the present invention are useful in the prophylaxis or treatment of metabolic disorders and complications thereof, such as, diabetes and obesity.
摘要翻译：本发明涉及作为代谢调节剂的式（I）的某些稠合芳基和杂芳基衍生物。因此，本发明的化合物可用于预防或治疗代谢紊乱及其并发症，例如糖尿病和肥胖症。

27. 发明申请

WO2004087669A1 NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF 审中-公开
标题翻译：新颖的喹啉，四氢喹诺酮和哌嗪衍生物及其使用相关的治疗方法
公开(公告)号：WO2004087669A1
公开(公告)日：2004-10-14
申请号：PCT/JP2004/004624
申请日：2004-03-31
申请人： TAISHO PHARMACEUTICAL CO. LTD. , ARENA PHARMACEUTICALS INC. , SEKIGUCHI, Yoshinori, , KANUMA, Kosuke, , OMODERA, Katsunori, , BUSUJIMA, Tsuyoshi, , TRAN, Thuy-Anh, , HAN, Sangdon, , CASPER, Martin, , KRAMER, Bryan, A., , SEMPLE, Graeme, , ZOU, Ning,
发明人： SEKIGUCHI, Yoshinori, , KANUMA, Kosuke, , OMODERA, Katsunori, , BUSUJIMA, Tsuyoshi, , TRAN, Thuy-Anh, , HAN, Sangdon, , CASPER, Martin, , KRAMER, Bryan, A., , SEMPLE, Graeme, , ZOU, Ning,
IPC分类号： C07D215/42
CPC分类号： C07D239/48 , C07D215/42 , C07D239/94 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D417/14
摘要： The present invention relates to novel compounds of the Formula (I): which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.
摘要翻译：本发明涉及作为MCH受体拮抗剂的式（I）的新化合物。这些组合物可用于药物组合物，其用途包括预防或治疗改善记忆功能，睡眠和觉醒，焦虑，抑郁，情绪障碍，癫痫发作，肥胖症，糖尿病，食欲和进食障碍，心血管疾病，高血压，血脂异常，心肌梗塞，包括贪食症，厌食症，包括躁狂抑郁症，精神分裂症，del妄，痴呆，压力，认知障碍，注意力缺陷障碍，药物滥用障碍和包括帕金森氏病，癫痫和成瘾在内的运动障碍的暴饮暴食症。

28. 发明申请

WO2004076413A2 SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF GLUCOSE METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS THEREOF 审中-公开
标题翻译：作为葡萄糖代谢物和丙肝的调节剂的替代性ARYL和异丙肾上腺素衍生物及其治疗
公开(公告)号：WO2004076413A2
公开(公告)日：2004-09-10
申请号：PCT/US2004/005555
申请日：2004-02-23
申请人： ARENA PHARMACEUTICALS, INC. , JONES, Robert, M. , SEMPLE, Graeme , CHOI, Jin, Sun, Karoline , XIONG, Yifeng , FIORAVANTI, Beatriz
发明人： JONES, Robert, M. , SEMPLE, Graeme , CHOI, Jin, Sun, Karoline , XIONG, Yifeng , FIORAVANTI, Beatriz
IPC分类号： C07D
CPC分类号： C07D401/04 , C07D211/14 , C07D211/62 , C07D401/10 , C07D401/12 , C07D401/14 , C07D413/04 , C07D413/12 , C07D417/14
摘要： The present invention relates to certain certain substituted aryl and heteroaryl derivatives as shown in Formula (Ia) that are modulators of metabolism. Accordingly, compounds of the present invention are useful in the prophylaxis or treatment of metabolic disorders and complications thereof, such as, diabetes and obesity.
摘要翻译：本发明涉及作为代谢调节剂的式（Ia）所示的某些取代的芳基和杂芳基衍生物。因此，本发明的化合物可用于预防或治疗代谢紊乱及其并发症，例如糖尿病和肥胖症。

29. 发明申请

WO2006127595A1 5-AMINOPYRAZOLE CARBOXYLIC ACID DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF 审中-公开
标题翻译： 5-氨基吡唑羧酸衍生物及其代谢相关疾病的治疗方法
公开(公告)号：WO2006127595A1
公开(公告)日：2006-11-30
申请号：PCT/US2006/019730
申请日：2006-05-23
申请人： ARENA PHARMACEUTICALS, INC. , SKINNER, Philip J. , SEMPLE, Graeme , WEBB, Peter
发明人： SKINNER, Philip J. , SEMPLE, Graeme , WEBB, Peter
IPC分类号： C07D231/38 , A61K31/415 , A61P3/00 , A61P3/04 , A61P3/06 , A61P3/10
CPC分类号： C07D231/38 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14
摘要： The present invention relates to certain pyrazole carboxylic acid or ester derivatives of Formula (I) and pharmaceutically acceptable salts thereof which exhibit useful pharmacological properties, for example, as agonists for the GPCR referred to herein as RUP38. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, such as, dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for the use of the compounds of the invention in combination with other active agents such as those belonging to the class of -glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers and the like.
摘要翻译：本发明涉及一些表现出有用的药理学性质的式（I）的吡唑羧酸或其酯衍生物及其药学上可接受的盐，例如本文称为RUP38的GPCR的激动剂。本发明还提供了含有本发明化合物的药物组合物，以及使用本发明化合物和组合物治疗代谢相关疾病如血脂异常，动脉粥样硬化，冠心病，胰岛素抵抗，类型 2型糖尿病，综合征X等。此外，本发明还提供本发明化合物与其它活性剂如属于葡糖苷酶抑制剂类，醛糖还原酶抑制剂，双胍类，HMG-CoA还原酶抑制剂，角鲨烯合成抑制剂，贝特类，LDL分解代谢增强剂，血管紧张素转换酶（ACE）抑制剂，胰岛素分泌增强剂等。

30. 发明申请

WO2005095357A3 PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF 审中-公开
标题翻译：吡嗪衍生物及其使用相关的治疗方法
公开(公告)号：WO2005095357A3
公开(公告)日：2006-01-19
申请号：PCT/JP2005006582
申请日：2005-03-29
申请人： TAISHO PHARMA CO LTD , ARENA PHARM INC , SEKIGUCHI YOSHINORI , KANUMA KOSUKE , OMODERA KATSUNORI , TRAN THUY-ANH , SEMPLE GRAEME , KRAMER BRYAN A
发明人： SEKIGUCHI YOSHINORI , KANUMA KOSUKE , OMODERA KATSUNORI , TRAN THUY-ANH , SEMPLE GRAEME , KRAMER BRYAN A
IPC分类号： C07D239/48 , A61K31/505 , A61P3/04 , A61P3/10 , C07D239/00 , C07D239/42 , C07D239/54 , C07D239/545 , C07D401/12 , C07D403/04 , C07D403/12 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D473/34 , C07D487/04
CPC分类号： C07D239/42 , C07D239/48 , C07D239/545 , C07D401/12 , C07D403/04 , C07D403/12 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D473/34 , C07D487/04
摘要： The present invention encompasses novel substituted pyrimidine compounds of Formula (I): which act as MCH receptor antagonists. These compounds are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.
摘要翻译：本发明包括式（I）的新型取代嘧啶化合物：其作为MCH受体拮抗剂。这些化合物可用于药物组合物，其用途包括预防或治疗改善记忆功能，睡眠和觉醒，焦虑，抑郁，情绪障碍，癫痫发作，肥胖症，糖尿病，食欲和进食障碍，心血管疾病，高血压，血脂异常，心肌梗死，包括贪食症，厌食症，包括躁狂抑郁症，精神分裂症，del妄，痴呆，压力，认知障碍，注意力缺陷障碍，药物滥用障碍和包括帕金森氏病，癫痫和成瘾在内的运动障碍的暴饮暴食症。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式